FIG 1.

Enrollment, random assignment, and flow of study patients. N2 = ipsilateral mediastinal lymph node metastasis; N3 = contralateral lymph node metastasis; unforeseen N2 disease/uN2 = pathologically proven N2 disease at lymph node dissection at the time of tumor resection when previous mediastinal staging showed N0 or N1. ^aMain reasons for declining study entry were objection to clinical trials/randomization and preference for additional staging certainty with mediastinoscopy. ^bCervical radiation fibrosis from a previous nonpulmonary malignancy. ^cMediastinal radiation fibrosis from a previous nonpulmonary malignancy. SCLC, small-cell lung cancer.